viewImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies subsidiary Talem Therapeutics inks deal with Ligand Pharmaceuticals for OmniAb platform

Ligand’s OmniAb is a genetically engineered platform for the generation of diverse human antibodies

Talem will access OmniAb to use with its own antibody discovery capabilities

ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) announced Tuesday that its wholly-owned subsidiary Talem Therapeutics signed a new agreement with Ligand Pharmaceuticals (NASDAQ:LGND) for its novel OmniAb platform.

Ligand’s OmniAb is a genetically engineered platform for the generation of diverse human antibodies. It is the only platform comprised of three species of rats, mice and chickens.

Under the agreement, Talem will access OmniAb to use with its own antibody discovery capabilities. The license enables Talem to develop and partner human antibodies across the platform.

READ: ImmunoPrecise Antibodies appoints industry veteran Brian Lundstrom to its board

Talem plans to leverage multiple tracks for antibody discovery within ImmunoPrecise’s technology portfolio, including the DeepDisplay custom immune phage libraries.

“ImmunoPrecise has years of experience successfully employing OmniAb animals in antibody discovery,” said Jennifer Bath, CEO of ImmunoPrecise in a statement.

“Combining ImmunoPrecise's end-to-end antibody discovery technologies with Ligand's leading OmniAb platform is a natural progression, supporting both companies' overall mission of getting the best therapeutic antibodies to the clinic faster, in this case, all under one roof.”

With the agreement in place, Talem hopes to streamline the path to the clinic by de-risking lead candidates for potential partners worldwide.

"Enabling Talem's internal discovery for the development of therapeutic antibodies in OmniAb animals provides Talem, and its future partners, a distinctively streamlined path to the clinic,” Bath told investors.

ImmunoPrecise also said that it had parted ways with Jason Orloske, its vice president of operations. The firm wished him well in his future endeavours.

Shares of ImmunoPrecise closed at C$0.60 in Toronto and at US$0.46 on OTC markets on Tuesday.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 2.44 CAD

Market: TSX-V
Market Cap: $195.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...


ImmunoPrecise Antibodies reveals 39% growth in 1Q revenue, initiates...

ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study. Bath says new...

3 weeks, 4 days ago

2 min read